免疫检查点抑制剂治疗小细胞肺癌的临床研究进展
[Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of Small Cell Lung Cancer].
作者信息
Huang Benlin, Duan Yong
机构信息
Department of Clinical Laboratory, the First Affiliated Hospital of Kunming Medical University; Yunnan Institute of Experimental Diagnosis; Yunnan Key Laboratory of Laboratory Medicine, Kunming 650032, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2019 Apr 20;22(4):239-244. doi: 10.3779/j.issn.1009-3419.2019.04.07.
With the in-depth study of tumor immunity, immunotherapy represented by immune checkpoint inhibitors has made a great breakthrough in solid tumors. Small cell lung cancer (SCLC) accounts for about 15%-20% of all lung cancers, with high malignancy, early metastasis and lack of effective treatment strategy. The appearance of immune checkpoint inhibitors brings new hope for SCLC. Several clinical trials have demonstrated the persistent efficacy and clinical activity of the programmed death receptor/ligand 1 (PD-1/L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) in the treatment of SCLC. However, its efficacy and safety are not very accurate, and the markers that can effectively predict the efficacy of immunotherapy have not been concluded. In this paper, for further changing the treatment strategy of SCLC clinical practice and providing theoretical basis of research, we reviewed the progress of immune checkpoint inhibitors, related markers in the treatment of SCLC by exploring the value, problems and challenges of immunotherapy in SCLC. .
随着肿瘤免疫研究的深入，以免疫检查点抑制剂为代表的免疫疗法在实体瘤治疗方面取得了重大突破。小细胞肺癌（SCLC）约占所有肺癌的15%-20%，具有高恶性、早期转移且缺乏有效治疗策略的特点。免疫检查点抑制剂的出现为小细胞肺癌带来了新希望。多项临床试验已证明程序性死亡受体/配体1（PD-1/L1）和细胞毒性T淋巴细胞相关抗原4（CTLA-4）在治疗小细胞肺癌方面具有持续疗效和临床活性。然而，其疗效和安全性并不十分确切，且尚未得出能够有效预测免疫治疗疗效的标志物。本文通过探讨免疫疗法在小细胞肺癌治疗中的价值、问题和挑战，回顾免疫检查点抑制剂及相关标志物的研究进展，以期进一步改变小细胞肺癌临床治疗策略并提供研究理论依据。
Zotero 插件